RedHill Biopharma Ltd. (NASDAQ: RDHL) today elaborated on the previously announced positive top-line results from the first Phase III study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s DiseaseAugust 1, 2018 8:16 AM Redhill Biopharma (RDHL) PT Raised to $28 at Nomura/InstinetJuly 30, 2018 1:00 PM Pre-Open Movers 07/30: (RDHL) (FDC) (CAT) Higher; (SNNA) (SOHU) (SODO) Lower (more...)July 30, 2018 9:27 AM RedHill Biopharma (RDHL) Reports Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s DiseaseJuly 30, 2018 7:07 AM